Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-11-16 00:00:00 ET · period of report 2023-11-14 · accession 0001209191-23-055610 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-11-16 | 2023-11-14+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 963.2K | +8% | +$166.5K |
| DM | 2023-11-16 | 2023-11-14+ | RXRX | Secora Michael | CFO | S - Sale+OE | $6.82 | -50.0K | 938.2K | -5% | -$341.0K |
| D | 2023-11-16 | 2023-11-15 | RXRX | Secora Michael | CFO | F - Tax | $7.18 | -7,172 | 931.0K | -0.8% | -$51.5K |
| DM | 2023-11-16 | 2023-11-14+ | RXRX | Secora Michael | CFO | M - OptEx | $0.00 | -75.0K | 1.19M | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-11-14 | M | A | 37,500 | $2.22 | 950,686 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-11-14 | S | D | 25,000 | $6.32 | 925,686 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $6.13 to $6.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Class A Common Stock | 2023-11-15 | F | D | 7,172 | $7.18 | 931,014 | D | — | — | |
| 4 | Common | Class A Common Stock | 2023-11-15 | S | D | 20,300 | $7.25 | 942,886 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $6.51 to $7.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 5 | Common | Class A Common Stock | 2023-11-15 | S | D | 4,700 | $7.62 | 938,186 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $7.51 to $7.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 6 | Common | Class A Common Stock | 2023-11-15 | M | A | 37,500 | $2.22 | 963,186 | D | — | — | |
| 7 | Derivative | Stock Option (Right to Buy) | 2023-11-14 | M | D | 37,500 | $0.00 | 1,222,635 | D | $2.22 · — to 2030-03-03 | 37,500 Class A Common Stock | (F7) The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. |
| 8 | Derivative | Stock Option (Right to Buy) | 2023-11-15 | M | D | 37,500 | $0.00 | 1,185,135 | D | $2.22 · — to 2030-03-03 | 37,500 Class A Common Stock | (F7) The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. |